Comparative in vivo evaluation of 2 Pioglitazone 30 mg Tablet formulations

Not Applicable

Not yet recruiting

• Conditions: Diabetes Mellitus.; Type 2 diabetes mellitus

• Registration Number: IRCT20180620040164N29
• Lead Sponsor: Hakim pharmaceutical Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Pending
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range between 18.5 - 30 kg/m2.
Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
Subjects that have normal vital signs.
Subjects who agree with patient consent form.

Exclusion Criteria

Subjects with known allergy to the products tested.
The subject has current or a history of cardiovascular, respiratory, neurological, endocrine, hematopoietic, immune, urinary, genital, gastrointestinal, hepatic, or psychiatric diseases or a history of epilepsy or convulsive seizures.
The subject has a fasting blood glucose level lower than 3.88 mmol/L.
The subject experienced acute infectious diseases within 4 weeks prior to Screening;
Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.
Subjects who has used any drug including prescription or Over-The-Counter (OTC) drugs within 14 days prior to the start of the study and might need drug intake during study period.
History of alcohol or drug abuse within 2 years before the start of the study.
Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity.
A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak Plasma Concentration (Cmax). Timepoint: E17 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 9, 10, 12, 24, 48 and 72 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Secondary Outcome Measures

Name	Time	Method
AUC (Area Under the Concentration-Time Curve). Timepoint: 17 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 9, 10, 12, 24, 48 and 72 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).